Nuclear Expression of P-STAT3 Is Associated with Poor Prognosis in ER(-) Breast Cancer

Overview

Journal Clin Pract

Publisher MDPI

Specialty General Medicine

Date 2022 Mar 22

PMID 35314590

Authors

Tsuyoshi Nakagawa

Goshi Oda

Hiroshi Kawachi

Toshiaki Ishikawa

Kentaro Okamoto

Hiroyuki Uetake

Affiliations

Soon will be listed here.

Abstract

The activation of signal transducer and activator of transcription 3 (STAT3) has been reported in several types of cancer, where it acts as an oncogene. However, in breast cancer, the clinical role of STAT3 remains unclear. In the present study, the association between phosphorylated-STAT3 (p-STAT3) expression and clinicopathological/biological factors was examined in each subtype. p-STAT3 expression was examined in 135 cases of breast cancer by immunohistochemistry. p-STAT3 expression was not associated with clinicopathological/biological factors and prognosis in a complete cohort of breast cancer cases. However, in patients with estrogen receptor-negative (ER(-)) breast cancer and triple-negative breast cancer (TNBC), multivariate analysis showed that higher p-STAT3 expression was significantly associated with a short relapse-free survival ( = 0.029, HR 5.37, 95%CI 1.19-24.29). TNBC patients with p-STAT3 overexpression were found to have a poor prognosis ( = 0.029, HR 5.37, 95%CI 1.19-24.29). On the other hand, in ER(+) breast cancer, p-STAT3 overexpression was associated with a favorable prognosis ( = 0.034, HR 9.48, 95%CI 1.18-76.21). The present results suggested that STAT3 expression may play a different role in ER(-) and ER(+) breast cancer. In the future, the pharmacological inhibition of STAT3 expression may serve as an effective therapeutic strategy for ER(-) breast cancer, particularly TNBC.

Citing Articles

Molecular pathways and targeted therapies in head and neck cancers pathogenesis.

Constantin M, Chifiriuc M, Bleotu C, Vrancianu C, Cristian R, Bertesteanu S Front Oncol. 2024; 14:1373821.

PMID: 38952548 PMC: 11215092. DOI: 10.3389/fonc.2024.1373821.

RNAi mediated silencing of STAT3/PD-L1 in tumor-associated immune cells induces robust anti-tumor effects in immunotherapy resistant tumors.

Ganesh S, Kim M, Lee J, Feng X, Ule K, Mahan A Mol Ther. 2024; 32(6):1895-1916.

PMID: 38549376 PMC: 11184339. DOI: 10.1016/j.ymthe.2024.03.035.

Accessing Apoptosis Induction and Metastasis Inhibition Effect of Magnolol on Triple Negative Breast Cancer .

Li Y, Wong C, Hsu F, Chen J, Yang C, Liu H In Vivo. 2023; 37(3):1028-1036.

PMID: 37103080 PMC: 10188043. DOI: 10.21873/invivo.13177.

STAT family of transcription factors in breast cancer: Pathogenesis and therapeutic opportunities and challenges.

Wong G, Manore S, Doheny D, Lo H Semin Cancer Biol. 2022; 86(Pt 3):84-106.

PMID: 35995341 PMC: 9714692. DOI: 10.1016/j.semcancer.2022.08.003.

c-Kit Induces Migration of Triple-Negative Breast Cancer Cells and Is a Promising Target for Tyrosine Kinase Inhibitor Treatment.

Lopez-Mejia J, Tallabs-Utrilla L, Salazar-Sojo P, Mantilla-Ollarves J, Sanchez-Carballido M, Rocha-Zavaleta L Int J Mol Sci. 2022; 23(15).

PMID: 35955836 PMC: 9369219. DOI: 10.3390/ijms23158702.

References

Sorlie T, Tibshirani R, Parker J, Hastie T, Marron J, Nobel A . Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A. 2003; 100(14):8418-23. PMC: 166244. DOI: 10.1073/pnas.0932692100. View

Bowman T, Garcia R, Turkson J, Jove R . STATs in oncogenesis. Oncogene. 2000; 19(21):2474-88. DOI: 10.1038/sj.onc.1203527. View

Walker S, Nelson E, Zou L, Chaudhury M, Signoretti S, Richardson A . Reciprocal effects of STAT5 and STAT3 in breast cancer. Mol Cancer Res. 2009; 7(6):966-76. DOI: 10.1158/1541-7786.MCR-08-0238. View

Niu G, Wright K, Huang M, Song L, Haura E, Turkson J . Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis. Oncogene. 2002; 21(13):2000-8. DOI: 10.1038/sj.onc.1205260. View

Jiang R, Jin Z, Liu Z, Sun L, Wang L, Li K . Correlation of activated STAT3 expression with clinicopathologic features in lung adenocarcinoma and squamous cell carcinoma. Mol Diagn Ther. 2012; 15(6):347-52. DOI: 10.1007/BF03256470. View

Arany I, Chen S, Megyesi J, Adler-Storthz K, Chen Z, Rajaraman S . Differentiation-dependent expression of signal transducers and activators of transcription (STATs) might modify responses to growth factors in the cancers of the head and neck. Cancer Lett. 2003; 199(1):83-9. DOI: 10.1016/s0304-3835(03)00345-8. View

Kanda Y . Investigation of the freely available easy-to-use software 'EZR' for medical statistics. Bone Marrow Transplant. 2012; 48(3):452-8. PMC: 3590441. DOI: 10.1038/bmt.2012.244. View

Horiguchi A, Oya M, Shimada T, Uchida A, Marumo K, Murai M . Activation of signal transducer and activator of transcription 3 in renal cell carcinoma: a study of incidence and its association with pathological features and clinical outcome. J Urol. 2002; 168(2):762-5. View

Elston C, Ellis I . Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology. 1991; 19(5):403-10. DOI: 10.1111/j.1365-2559.1991.tb00229.x. View

10.

Kusaba T, Nakayama T, Yamazumi K, Yakata Y, Yoshizaki A, Nagayasu T . Expression of p-STAT3 in human colorectal adenocarcinoma and adenoma; correlation with clinicopathological factors. J Clin Pathol. 2005; 58(8):833-8. PMC: 1770863. DOI: 10.1136/jcp.2004.023416. View

11.

Wei D, Le X, Zheng L, Wang L, Frey J, Gao A . Stat3 activation regulates the expression of vascular endothelial growth factor and human pancreatic cancer angiogenesis and metastasis. Oncogene. 2003; 22(3):319-29. DOI: 10.1038/sj.onc.1206122. View

12.

Chen Y, Wang J, Wang X, Liu X, Li H, Lv Q . STAT3, a Poor Survival Predicator, Is Associated with Lymph Node Metastasis from Breast Cancer. J Breast Cancer. 2013; 16(1):40-9. PMC: 3625768. DOI: 10.4048/jbc.2013.16.1.40. View

13.

Sonnenblick A, Salgado R, Brohee S, Zahavi T, Peretz T, Van den Eynden G . p-STAT3 in luminal breast cancer: Integrated RNA-protein pooled analysis and results from the BIG 2-98 phase III trial. Int J Oncol. 2017; 52(2):424-432. PMC: 6903891. DOI: 10.3892/ijo.2017.4212. View

14.

Nakagawa T, Iida S, Osanai T, Uetake H, Aruga T, Toriya Y . Decreased expression of SOCS-3 mRNA in breast cancer with lymph node metastasis. Oncol Rep. 2007; 19(1):33-9. View

15.

Sato T, Neilson L, Peck A, Liu C, Tran T, Witkiewicz A . Signal transducer and activator of transcription-3 and breast cancer prognosis. Am J Cancer Res. 2011; 1(3):347-55. PMC: 3138712. View

16.

McDaniel J, Varley K, Gertz J, Savic D, Roberts B, Bailey S . Genomic regulation of invasion by STAT3 in triple negative breast cancer. Oncotarget. 2016; 8(5):8226-8238. PMC: 5352396. DOI: 10.18632/oncotarget.14153. View

17.

Watson C, Miller W . Elevated levels of members of the STAT family of transcription factors in breast carcinoma nuclear extracts. Br J Cancer. 1995; 71(4):840-4. PMC: 2033751. DOI: 10.1038/bjc.1995.162. View

18.

Dhir R, Ni Z, Lou W, DeMiguel F, Grandis J, Gao A . Stat3 activation in prostatic carcinomas. Prostate. 2002; 51(4):241-6. DOI: 10.1002/pros.10079. View

19.

Bromberg J, Wrzeszczynska M, Devgan G, Zhao Y, Pestell R, Albanese C . Stat3 as an oncogene. Cell. 1999; 98(3):295-303. DOI: 10.1016/s0092-8674(00)81959-5. View

20.

Kamran M, Patil P, Gude R . Role of STAT3 in cancer metastasis and translational advances. Biomed Res Int. 2013; 2013:421821. PMC: 3807846. DOI: 10.1155/2013/421821. View